Blocking the Horizon-Amgen deal will be worse for pharma than for biotech, says Mizuho’s Jared Holz

Jared Holz, Mizuho healthcare sector strategist, joins ‘Fast Money’ to discuss merger and acquisition crackdowns in the biotech space, government regulation in the space, and more.